Sanofi, United States
Disclosure information not submitted.
SP03K - Disease Severity and Outcomes Among Patients with Rheumatoid Arthritis Who Receive a Newly Approved Biologic: Real-world US Experience with Sarilumab from the ACR RISE Registry
Tuesday, August 24, 20213:30 PM – 4:45 PM US Eastern Time